Loading
Cell therapies made from healthy donors in advance, so patients do not have to wait for their own cells to be engineered.
Allogeneic cell therapy manufactures engineered cells from healthy donors in advance: TRAC knockout prevents graft-versus-host disease, and B2M/HLA editing or CD52 knockout with alemtuzumab conditioning delays rejection by the patient's immune system. Gene-edited donor T cells (Allogene cema-cel, ALLO-316 against CD70; Caribou; CRISPR Therapeutics) and iPSC-derived platforms (Fate, Century) are the main approaches. The appeal is immediate availability and industrial scale, removing the manufacturing wait that patients with fast-moving disease cannot afford. Persistence is the main limitation, because host rejection eventually clears the donor cells, and deeper lymphodepletion is needed to hold it off. The simple version is a cell therapy taken off the shelf rather than made from each patient's own cells.
TRAC knockout prevents GVHD; B2M/HLA editing or CD52 knockout with alemtuzumab conditioning delays host rejection.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Tregzi, formerly Orca-T, is a donor stem cell transplant sorted with high precision and given with regulatory T cells, so that patients with blood cancers keep the graft's anti-cancer effect while being protected from chronic graft-versus-host disease. The FDA approved it on 30 June 2026 for adults having a matched-donor transplant.
Zemcelpro is a laboratory-expanded umbilical cord blood transplant for adults with blood cancers who need a donor stem cell transplant but have no suitable matched donor; expanding the cells lets a single small cord blood unit be enough.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
The UCART19 report was the first clinical evidence that a universal, pre-manufactured CAR-T made from a donor can work, avoiding the weeks of autologous manufacturing and the problem of patients whose own T cells are too damaged. It set the template for later allogeneic programmes (including cemacabtagene autoleucel in the ALPHA studies) and for in vivo CAR generation. Short persistence and the need for deep lymphodepletion remain the central weaknesses.
Query for this technology: (TITLE:"allogeneic CAR T" OR ABSTRACT:"allogeneic CAR T" OR TITLE:"off-the-shelf CAR T" OR ABSTRACT:"off-the-shelf CAR T" OR TITLE:"allogeneic CAR-T" OR ABSTRACT:"allogeneic CAR-T"). Results are unfiltered search hits about Allogeneic (off-the-shelf) cell therapy, not a curated reading list.
Shares Allotera Therapeutics (formerly Wugen), Imugene, Dorocubicel (UM171-expanded cord blood), Stephen J. Forman.
Shares Adicet Bio, Hans-Peter Kiem, Sana Biotechnology, UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL.
Shares Children's Cancer Hospital Egypt 57357, Christian Medical College, Vellore, King Hussein Cancer Center, National Cancer Institute, Cairo University.